Our leadership
Home / Our company / Our leadership
Jump to section
Our leadership, which includes our Board of Directors and Senior Executive Team, is accountable to our shareholders for the responsible conduct of the business and our long-term success. It also represents the interests of all our stakeholders in ensuring that we deliver for patients by putting science at the heart of everything we do.
Board of Directors
Our Directors are collectively responsible for the success of AstraZeneca. In addition, the Non-Executive Directors are responsible for exercising independent and objective judgement and for scrutinising and challenging management. The Board is responsible for setting our strategy and policies, oversight of risk and corporate governance and monitoring progress towards meeting our annual plans. It is accountable to our shareholders for the proper conduct of the business and our long-term success and represents the interests of all stakeholders. The Board has delegated some of its powers to five principal committees and the CEO. Members of the Board and their biographies are shown below.
Michel Demaré
Non-Executive Chair of the Board
Member of the Board since September 2019 and Chair since April 2023.
Michel Demaré
Non-Executive Chair of the Board
Member of the Board since September 2019 and Chair since April 2023.
Committee membership: Chair of the Nomination and Governance Committee and member of the Remuneration Committee.
Skills and experience: Michel was previously Vice-Chairman of UBS Group AG (2010 to 2019), Chairman of Syngenta and the Syngenta Foundation for Sustainable Agriculture (2013 to 2017) and Chairman of SwissHoldings (2013 to 2015). Between 2005 and 2013, Michel was CFO of ABB Ltd and also acting interim CEO during 2008. He joined ABB from Baxter International Inc., where he was CFO Europe from 2002 to 2005. Prior to that, he spent 18 years at The Dow Chemical Company, in several international finance functions, including the CFO of Dow’s Global Polyolefins and Elastomers division between 1997 and 2002. He began his career as a banking officer at Continental Illinois’ Belgian subsidiary. Michel graduated with an MBA from the Katholieke Universiteit Leuven, Belgium, and holds a degree in applied economics from the Université Catholique de Louvain, Belgium.
Other appointments: Michel is a Non-Executive Director of Vodafone Group Plc and Louis Dreyfus Int’l Holdings BV, Chairman of IMD Business School.
Pascal Soriot
Executive Director and Chief Executive Officer
Member of the Board and CEO since October 2012.
Pascal Soriot
Executive Director and Chief Executive Officer
Member of the Board and CEO since October 2012
Skills and experience: Pascal brings a passion for science and medicine as well as significant experience in established and emerging markets, strength of strategic thinking, a successful track record of managing change and executing strategy, and the ability to lead a diverse organisation. He served as Chief Operating Officer of Roche’s pharmaceuticals division from 2010 to September 2012 and, prior to that, Chief Executive Officer of Genentech, a biologics business, where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior management roles in numerous major companies around the world. He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from HEC, Paris.
Pascal received a British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic in the Queen’s Birthday Honours 2022.
Other appointments: Pascal is on the Board of Sustainable Markets Initiative Limited.
Aradhana Sarin
Executive Director and Chief Financial Officer
Member of the Board and CFO since August 2021.
Aradhana Sarin
Executive Director and Chief Financial Officer
Member of the Board and CFO since August 2021
Skills and experience: Prior to her current role, Aradhana was CFO for Alexion. Aradhana joined Alexion in 2017 and was responsible for driving strategic growth, financial performance and business development at Alexion. She brings operational experience in biopharma plus more than 20 years of professional experience at global financial institutions and has extensive knowledge of global healthcare systems, having closed more than 100 transactions across M&A, equity and debt financing. Before joining Alexion, Aradhana was Managing Director of Healthcare Corporate and Investment Banking at Citi Global Banking, focusing on clients in the life sciences and biopharmaceutical sectors. Previously, she served as Managing Director of Healthcare Investment Banking at UBS, and worked at JP Morgan in the M&A Advisory and Healthcare groups. Aradhana trained as a medical doctor in India and spent two years practising in both India and Africa. She completed her medical training at the University of Delhi and received her MBA from Stanford Business School.
Other appointments: Aradhana is on the Board of Governors of the American Red Cross and an independent director of Anheuser-Busch InBev.
Philip Broadley
Senior independent Non-Executive Director
Member of the Board since April 2017 and Senior independent Non-Executive Director since March 2021.
Philip Broadley
Senior independent Non-Executive Director
Member of the Board since April 2017 and Senior independent Non-Executive Director since March 2021
Committee membership: Chair of the Audit Committee and member of the Remuneration Committee and Nomination and Governance Committee
Skills and experience:
Philip has significant financial and international business experience, having previously been Group Finance Director of Prudential plc for eight years and Old Mutual plc for six years. He started his career at Arthur Andersen where he was a partner for seven years. He is a past Chairman of the 100 Group of Finance Directors in the UK. Philip was also previously a board member and Chairman of the Audit Committee of Stallergenes Greer plc. He is a Fellow of the Institute of Chartered Accountants in England and Wales. Philip graduated in Philosophy, Politics and Economics from St Edmund Hall, Oxford, where he is now a St Edmund Fellow, and holds an MSc in Behavioural Science from the London School of Economics. Until March 2019, Philip was a member of the Oxford University Audit Committee.
Other appointments: Philip is the Non-Executive Chair of Lancashire Holdings Limited and serves as a Non-Executive Director of Legal & General Group plc.
Euan Ashley
Non-Executive Director
Member of the Board since October 2020.
Euan Ashley
Non-Executive Director
Member of the Board since October 2020
Committee membership: Chair of the Science Committee and member of the Nomination and Governance Committee.
Skills and experience: Euan studied physiology and medicine at Glasgow University, completing his junior doctor training at Oxford University Hospitals NHS Trust, before undertaking a DPhil in cardiovascular cellular biology and molecular genetics at the University of Oxford. In 2002, Euan moved to Stanford University in California to train in cardiology and advanced heart failure. At Stanford University, Euan’s research focuses on genetic mechanisms of cardiovascular health and disease. In addition to wet bench science, his laboratory leverages artificial intelligence and digital health tools, working with biotechnology and technology partners in Silicon Valley, to advance both translational and clinical research. Euan has received many awards including recognition from the Obama White House for contributions to personalized medicine and the American Heart Association's Medal of Honor for precision medicine.
Other appointments: Euan is Associate Dean, Professor of Biomedical Data Science and Professor of Cardiovascular Medicine and Genetics at Stanford University in California.
Deborah DiSanzo
Non-Executive Director
Member of the Board since December 2017.
Deborah DiSanzo
Non-Executive Director
Member of the Board since December 2017
Committee Membership: Member of the Audit Committee
Skills and experience: Deborah DiSanzo is President of Best Buy Health for Best Buy Co. Inc. In this role, she is responsible for the company’s health strategy, connecting people with technology to enable care at home.
Deborah oversees Best Buy Health's three focal areas of consumer health, active aging, and virtual care. Her oversight of Best Buy Health includes Lively!, the brand of connected health and personal emergency response services to the aging population, which Best Buy acquired in 2018 as well as Current Health, a leading care at home technology company which Best Buy acquired in 2021. She leads incubation, strategy and corporate development teams focused on scaling health initiatives at Best Buy.
Deborah is an innovative, strategic leader with more than 30 years’ experience at the intersection of health care and technology. She is a recognized thought leader in artificial intelligence and big data, has deep experience in running businesses known for their innovation in health care, and has a demonstrated ability to drive growth both organically and through acquisitions.
Prior to Best Buy, Deborah was the General Manager of IBM Watson Health, launching artificial intelligence offerings designed to help doctors, researchers, health care providers, pharmacists and insurers better serve patients around the world. Deborah was also CEO of Philips Healthcare, where among many other innovation activities, she and her team brought consumer-grade, automatic defibrillators to the market, making them first available in public places then, ultimately, in the homes of Americans across the country. Deborah teaches AI in Health and Managing Information in Health Care at the Harvard TH Chan School of Public Health.
Deborah holds a bachelor’s degree from Merrimack College and an MBA from Babson College. She is an Harvard University Advanced Leadership Initiative 2019 Fellow.
Other appointments: Deborah is President of Best Buy Health for Best Buy Co. Inc.
Diana Layfield
Non-Executive Director
Member of the Board since November 2020.
Diana Layfield
Non-Executive Director
Member of the Board since November 2020
Committee Membership: Member of the Science Committee
Skills and experience: Diana has broad global business experience which began in the pharmaceutical and biotech sector. She has held senior leadership roles in the technology sector and international banking, including senior positions at Standard Chartered Bank, as the CEO of a start-up technology company, and in Healthcare and Life Sciences at McKinsey & Co..
Until December 2020, Diana was a Non-Executive Director and a member of the Audit, Ethics and Corporate Responsibility, and Nomination Committees of Aggreko plc.
Diana has a BA from Oxford University and an MA in Public Administration and International Economics from Harvard University.
Other appointments: Diana is General Manager, International Search at Google, leading the development of Google Search internationally, including product and engineering. She was also President, EMEA Partnerships and VicePresident, ‘Next Billion Users” where she drove the development of products and services for future Google users. She is the Chair of British International Investment plc (BII), the UK’s Development Finance Institution, which has $8bn of investments across emerging markets to support economic development, and a Council Member of the London School of Hygiene & Tropical Medicine.
Anna Manz
Non-Executive Director
Member of the Board since September 2023.
Anna Manz
Non-Executive Director
Member of the Board since September 2023
Committee Membership: Member of the Audit Committee.
Skills and experience: Anna joined Nestlé S.A. as Chief Financial Officer and a member of Nestlé’s Executive Board in March 2024. Prior to this, Anna was Chief Financial Officer and a member of the Board of Directors of London Stock Exchange Group plc from 2020 to February 2024. From 2016 - 2020, she was an Executive Director and the Chief Financial Officer of Johnson Matthey Plc and led its Finance, Procurement and IT functions. Prior to joining Johnson Matthey, Anna spent 17 years at Diageo plc in a number of senior finance roles, including Chief Strategy Officer and as a member of the Executive Committee. She brings extensive expertise in accounting, corporate finance and mergers and acquisitions, as well as experience of business diversification and transformation. Anna was a Non-Executive Director of ITV plc from 2016 – 2023 and served on its Audit Committee and Remuneration Committee for most of that period.
Sheri McCoy
Non-Executive Director
Member of the Board since October 2017.
Sheri McCoy
Non-Executive Director
Member of the Board since October 2017
Committee Membership: Chair of the Remuneration Committee and member of the Audit Committee, the Sustainability Committee and the Nomination and Governance Committee.
Skills and experience: Until February 2018, Sheri was Chief Executive Officer and a Director of Avon Products, Inc. Prior to joining them in 2012, she had a distinguished 30-year career at Johnson & Johnson, latterly serving as Vice Chairman of the Executive Committee, responsible for the Pharmaceuticals and Consumer business segments. Sheri joined Johnson & Johnson as an R&D scientist and subsequently managed businesses in every major product sector, holding positions including Worldwide Chairman, Surgical Care Group and Division President, Consumer. She holds a Bachelor of Science degree in textile chemistry from the University of Massachusetts Dartmouth, a Master’s degree in chemical engineering from Princeton University and an MBA from Rutgers University, both in New Jersey, US.
Other appointments: Sheri serves on the boards of Stryker, Kimberly-Clark, and Sail Biomedicines. She is also an industrial adviser for EQT, and in connection serves on the boards of Galderma, Parexel and is Chair of Dechra.
Tony Mok
Non-Executive Director
Member of the Board since January 2019.
Tony Mok
Non-Executive Director
Member of the Board since January 2019
Committee membership: Member of the Science Committee
Skills and experience: Tony is the Li Shu Fan Medical Foundation endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. His work includes multiple aspects of lung cancer research, with his main focus on biomarker and molecular targeted therapy in lung cancer. He has led and co-led multiple international Phase III trials, including as the principal investigator and first author on the landmark Iressa Pan-Asia Study, which confirmed the application of precision medicine for advanced lung cancer. He has also contributed to the development of clinical research infrastructure in China and Asia. Tony is the Past President of International Association for the Study of Lung Cancer, and a past Board member of the American Society of Clinical Oncology. His work has been recognised by numerous awards including the ESMO Lifetime Achievement Award in 2018 and Giant of Cancer Care in 2020. He was awarded with the Bronze Bauhinia Star (BBS) by the Government of Hong Kong Special Administrative Region in 2022 to recognize his dedicated service in public affairs.
Other appointments: Tony is a Non-Executive Director of HUTCHMED (China) Limited (Chair of Nomination Committee and Technical Committee, a member of the Sustainability Committee), a member of the Scientific Advisory Board of Prenetics Global Limited and serves on the board of Insighta.
Nazneen Rahman
Non-Executive Director
Member of the Board since June 2017.
Nazneen Rahman
Non-Executive Director
Member of the Board since June 2017
Committee membership: Chair of the Sustainability Committee, and member of the Nomination and Governance Committee, Remuneration Committee and Science Committee.
Skills and experience: Nazneen has significant scientific, medical and data analysis experience in rare disease and cancer genomics. She was Head of the Division of Genetics and Epidemiology at the Institute of Cancer Research, London, and Head of Cancer Genetics at the Royal Marsden NHS Foundation Trust to 2018. Nazneen was also founder and Director of the TGLclinical Genetic Testing Laboratory, which delivered fast, affordable, cancer gene testing to the NHS. As founder and CEO of YewMaker and Director of the Sustainable Medicines Partnership she is now delivering science-based solutions to make healthcare more sustainable. Nazneen qualified in medicine from Oxford University in 1991, gained her Certificate of Completion of Specialist Training in medical genetics in 2001 and a PhD in molecular genetics in 1999. She has a strong commitment to open science and has garnered numerous awards, including a CBE in recognition of her contribution to medical sciences.
Other appointments: Nazneen is founder and CEO of YewMaker and Director of the Sustainable Medicines Partnership
Andreas Rummelt
Non-Executive Director
Member of the Board since August 2021.
Andreas Rummelt
Non-Executive Director
Member of the Board since August 2021
Committee membership: Member of the Sustainability Committee.
Skills and experience: Andreas joined the Board following the acquisition of Alexion, where he had been a director since 2010. Andreas was previously at Novartis where he served on the Executive Committee from 2006 until 2010. He had been Group Head of Technical Operations and Quality from 2009 until 2010. He was Global CEO of Sandoz, the Generics Division of Novartis, from 2004 to 2008, having originally joined in 1985. Until May 2023, Andreas was a member of the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership. Andreas earned his PhD in pharmaceutical sciences from the University of Erlangen-Nuremberg and received his executive training in general management and leadership from IMD in Lausanne, INSEAD in Fontainebleau and Harvard Business School.
Other appointments: Andreas is Chairman of InterPharmaLink AG since 2011 and a director of various privately-held biotech and pharmaceutical companies.
Marcus Wallenberg
Non-Executive Director
Member of the Board since April 1999.
Marcus Wallenberg
Non-Executive Director
Member of the Board since April 1999
Committee membership: Member of the Science Committee and member of the Sustainability Committee
Skills and experience: Marcus has international business experience across various industry sectors, including the pharmaceutical industry from his directorship with Astra prior to 1999.
Other appointments: Marcus is Chair of Skandinaviska Enskilda Banken AB, Saab AB and FAM AB. He is Vice-Chair of Investor AB and Vice-Chair of EQT AB. Marcus is also Chair of The Royal Swedish Academy of Engineering Sciences and aBoard member of the Knut and Alice Wallenberg Foundation.
Senior Executive Team
In addition to the Board of Directors, our Senior Executive Team, or SET, is the body through which our Chief Executive Officer (CEO) exercises the authority delegated to him by the Board. Our CEO leads the SET and has executive responsibility for the management, development and performance of the business. The Chief Executive Officer, Chief Financial Officer and SET also take the lead in developing our strategy for review, constructive challenge and approval by the Board as part of our annual strategy review process.
Pascal Soriot
Executive Director and Chief Executive Officer
Pascal Soriot
Executive Director and Chief Executive Officer
Member of the Board and CEO since October 2012
Skills and experience: Pascal brings a passion for science and medicine as well as significant experience in established and emerging markets, strength of strategic thinking, a successful track record of managing change and executing strategy, and the ability to lead a diverse organisation. He served as Chief Operating Officer of Roche’s pharmaceuticals division from 2010 to September 2012 and, prior to that, Chief Executive Officer of Genentech, a biologics business, where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior management roles in numerous major companies around the world. He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from HEC, Paris.
Pascal received a British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic in the Queen’s Birthday Honours 2022.
Other appointments: Pascal is on the Board of Sustainable Markets Initiative Limited.
Aradhana Sarin
Executive Director and Chief Financial Officer
Aradhana Sarin
Executive Director and Chief Financial Officer
Member of the Board and CFO since August 2021
Skills and experience: Prior to her current role, Aradhana was CFO for Alexion. Aradhana joined Alexion in 2017 and was responsible for driving strategic growth, financial performance and business development at Alexion. She brings operational experience in biopharma plus more than 20 years of professional experience at global financial institutions and has extensive knowledge of global healthcare systems, having closed more than 100 transactions across M&A, equity and debt financing. Before joining Alexion, Aradhana was Managing Director of Healthcare Corporate and Investment Banking at Citi Global Banking, focusing on clients in the life sciences and biopharmaceutical sectors. Previously, she served as Managing Director of Healthcare Investment Banking at UBS, and worked at JP Morgan in the M&A Advisory and Healthcare groups. Aradhana trained as a medical doctor in India and spent two years practising in both India and Africa. She completed her medical training at the University of Delhi and received her MBA from Stanford Business School.
Other appointments: Aradhana is on the Board of Governors of the American Red Cross and an independent director of Anheuser-Busch InBev.
Sharon Barr
Executive Vice-President, BioPharmaceuticals R&D
Sharon Barr
Executive Vice-President, BioPharmaceuticals R&D
Skills and experience: Sharon was appointed as Executive Vice-President, BioPharmaceuticals R&D in August 2023. She is responsible for discovery through to late-stage development across CVRM and Respiratory & Immunology. Prior to this role, Sharon served as Senior Vice President, Head of Research and Product Development of Alexion, AstraZeneca Rare Disease having joined in 2013. With more than 18 years of industry experience she has previously led translational research, precision medicines, and global drug development teams. Sharon received her PhD in molecular biology from New York University, and completed a postdoctoral fellowship focused on mechanisms of DNA Damage and Repair at Stanford University. In 2022, Sharon was recognised as a Healthcare Businesswoman’s Association Luminary in recognition of her transformational leadership and passion for mentoring those around her.
Pam Cheng
Executive Vice President, Global Operations, IT & Chief Sustainability Officer
Pam Cheng
Executive Vice President, Global Operations, IT & Chief Sustainability Officer
Skills and experience: Pam was appointed Executive Vice-President, Operations & Information Technology in June 2015 and assumed additional responsibility for the AstraZeneca Sustainability strategy and function in January 2023. Pam joined AstraZeneca after having spent 18 years with Merck/MSD in Global Manufacturing and Supply Chain and Commercial roles. Pam was the Head of Global Supply Chain Management & Logistics for Merck and led the transformation of Merck supply chains across the global supply network. Pam also held the role of President of MSD China, responsible for MSD’s entire business in China. Prior to joining Merck, Pam held various engineering and project management positions at Universal Oil Products, Union Carbide Corporation and GAF Chemicals. Pam holds Bachelor’s and Master’s degrees in chemical engineering from Stevens Institute of Technology in New Jersey and an MBA in marketing from Pace University in New York.
Other appointments: Pam serves as a Non-Executive Director of the Smiths Group plc Board and as a Trustee Member of the Board for Stevens Institute of Technology. Pam also serves as an Advisor to the International Society of Pharmaceutical Engineering (ISPE) Board of Directors.
Ruud Dobber
Executive Vice-President, BioPharmaceuticals Business Unit
Ruud Dobber
EVP and President, BioPharmaceuticals Business Unit
Skills and experience: Ruud was appointed Executive Vice-President, BioPharmaceuticals Business Unit in January 2019 and is responsible for product strategy and commercial delivery for CVRM, Respiratory and Immunology, and Vaccines & Immune Therapies. Prior to this, Ruud held the role of Executive Vice-President, North America and was responsible for driving growth and maximising the contribution of the commercial operations in North America. Ruud joined Astra (later to become AstraZeneca) in 1997 and has assumed leadership roles with increasing responsibility including Executive Vice-President, North America; Executive Vice-President, Europe; Regional Vice-President, Europe, Middle East and Africa; and Regional Vice-President, Asia Pacific. Ruud served as a member of the board and executive committee of the European Federation of Pharmaceutical Industries and Associations and was previously Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America. Ruud holds a doctorate in immunology from the University of Leiden, Netherlands, beginning his career as a research scientist in immunology and ageing.
Other appointments: Ruud was appointed as a non-executive director of the Board of Almirall S.A. in June 2021.
Marc Dunoyer
Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca
Marc Dunoyer
Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca
Skills and experience: Marc became CEO of Alexion, AstraZeneca’s Rare Disease group, in August 2021 following its acquisition in July. He had previously served as an Executive Director and AstraZeneca’s Chief Financial Officer from November 2013. Marc’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GSK, has given him extensive industry experience. He is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, Global Product and Portfolio Strategy from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK Japan. He holds an MBA from HEC Paris and a Bachelor of Law degree from Paris University.
Other appointments: Marc is a member of the Boards of JCR Pharmaceuticals and Cellectis.
David Fredrickson
Executive Vice-President, Oncology Business Unit
David Fredrickson
Executive Vice-President, Oncology Business Unit
Skills and experience: Dave was appointed Executive Vice-President, Oncology Business Unit in October 2017 and is responsible for driving growth and maximising the commercial performance of the AstraZeneca global Oncology portfolio. He has global accountability for marketing, sales, medical affairs and market access in Oncology and plays a critical leadership role in setting the Oncology portfolio and product strategy. Previously, Dave served as President of AstraZeneca K.K. in Japan, and Vice-President, Specialty Care in the US. While in Japan, Dave also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a Director of the Japan Pharmaceutical Manufacturers Association. Before joining AstraZeneca, Dave worked at Roche/Genentech, where he served in several functions and leadership positions, including Oncology Business Unit Manager in Spain, and strategy, marketing and sales roles in the US. Prior to this, Dave worked at the Monitor Group, LLC (now Monitor Deloitte Group, LLC), a global strategy consultancy. Dave is a graduate of Georgetown University in Washington DC.
Other appointments: Dave was appointed to the Board of Directors of Caris Life Sciences in August 2024.
Susan Galbraith
Executive Vice-President, Oncology R&D
Susan Galbraith
Executive Vice-President, Oncology R&D
Skills and experience: Susan was appointed as Executive Vice-President, Oncology R&D in July 2021, with responsibility for transforming the productivity and scientific output from Oncology R&D. Over her career, Susan has helped develop 12 approved medicines. A Clinical Oncologist by background, Susan studied medicine at Manchester and Cambridge Universities and has a PhD from the University of London. In recognition of her contributions to Oncology drug development, she has been awarded an honorary Doctorate of Medical Science from the Institute of Cancer Research (ICR), is a Fellow of the Academy of Medical Sciences and elected to the Academy of the American Association for Cancer Research (AACR). Susan is a member of the Cambridge Cancer Centre Executive Committee and the Scientific Advisory Board of the ICR. From 2021 to 2024 she served on the Board of Directors of the AACR and currently serves on the European Association of Cancer Research (EACR) Advisory Council.
Jeff Pott
Chief Human Resources Officer, Chief Compliance Officer and General Counsel
Jeff Pott
Chief Human Resources Officer, Chief Compliance Officer and General Counsel
Skills and experience: Jeff was appointed General Counsel in January 2009 and has overall responsibility for all aspects of AstraZeneca’s Legal and IP function. In addition to his role as General Counsel, he was appointed Chief Human Resources Officer in January 2021 assuming additional responsibilities for the AstraZeneca Human Resources function and was appointed Chief Compliance Officer in January 2023. Jeff joined AstraZeneca in 1995 and has worked in various litigation roles, where he has had responsibility for IP, anti-trust and product liability litigation. Before joining AstraZeneca, he spent five years at the US legal firm Drinker Biddle and Reath LLP, where he specialised in pharmaceutical product liability litigation and anti-trust advice and litigation. He received his Bachelor’s degree in political science from Wheaton College and his Juris Doctor Degree from Villanova University School of Law.
Iskra Reic
Executive Vice-President, International
Iskra Reic
Executive Vice-President, International
Skills and experience: Iskra was appointed as Executive Vice-President, International in December 2024. She is responsible for overall strategy and driving sustainable growth across the International region, which includes China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand.
Prior to this role, Iskra held the role of EVP, Vaccines & Immune Therapies, where she was responsible for both the early and late-stage development of the Unit’s pipeline and portfolio, including COVID-19 and RSV vaccines and monoclonal antibodies, strategic partnerships and acquisitions, medical affairs and commercial operations. Iskra has served on AstraZeneca’s Senior Executive Team since 2017 when she was EVP for Europe & Canada. She has also held senior roles across Central & Eastern Europe, Middle East and Africa, and Eurasia.
Iskra has a PhD in Strategy and Leadership and an International Executive MBA in Business and Leadership from the IEDC-Bled School of Management, Slovenia. She also holds a DMD from the Medical University of Zagreb.
Other appointments: Iskra was appointed as a non-executive director of the Board of Directors of myTomorrows in July 2024. She is also a member of the Steering Committee of the Partnership for Health System Sustainability and Resilience.